Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TMHC files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTaylor Morrison clears HSR antitrust review for Berkshire Hathaway acquisition
Filed July 7, 2026 · Period ending July 6, 2026 · ~1 min read
Key Changes
-
high
Hart-Scott-Rodino antitrust waiting period expired July 6, 2026, removing one regulatory hurdle for Berkshire Hathaway's acquisition of Taylor Morrison.
Item 8.01 verify on EDGAR → -
high
Merger remains subject to shareholder approval (majority of outstanding shares) and other regulatory clearances before closing.
Item 8.01 verify on EDGAR → -
high
Under May 31, 2026 merger agreement, Taylor Morrison will become a wholly owned subsidiary of Berkshire Hathaway.
Item 8.01 verify on EDGAR →
Summary
Taylor Morrison announced that the Hart-Scott-Rodino antitrust waiting period for Berkshire Hathaway's proposed acquisition expired on July 6, 2026. This milestone removes federal antitrust objections as a barrier to the deal, which was announced May 31, 2026. The transaction still requires a shareholder vote, with approval needed from a majority of outstanding common shares.
Other regulatory approvals remain pending. A proxy statement has been filed and mailed to shareholders for the vote. Until shareholders approve the merger and remaining regulatory conditions are satisfied, the deal cannot close. For Taylor Morrison shareholders, the key event to watch is the upcoming shareholder vote, which will determine whether the Berkshire Hathaway acquisition proceeds.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
The HSR Waiting Period expired at 11:59 pm Eastern Time on July 6, 2026.
The Hart-Scott-Rodino antitrust waiting period for Berkshire Hathaway's proposed acquisition of Taylor Morrison has expired. This removes one regulatory hurdle for the merger, though the transaction still requires shareholder approval and other regulatory clearances before it can close.
Added in current filing · verify on EDGAR →
The closing of the Merger remains subject to the receipt of other required regulatory approvals, adoption of the Merger Agreement by the holders of a majority of the Company’s outstanding common stock entitled to vote thereon, as well as other customary closing conditions.
While the HSR waiting period has expired, the merger cannot close until shareholders vote to approve it and other regulatory approvals are obtained. The company has filed a proxy statement for the shareholder vote, which has been mailed to stockholders.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 7, 2026 · How we verify